Lb Pharmaceuticals (LBRX) Short term Debt (2024 - 2026)

Lb Pharmaceuticals has reported Short term Debt for 3 years, with the latest figure at $1.1 million in Q1 2026.

• For the quarter ending Q1 2026, Short term Debt changed N/A year-over-year to $1.1 million; the trailing twelve-month figure through Mar 2026 stood at $1.1 million (changed N/A YoY), and the FY2025 full-year result was $1.3 million, down 46.37% from the prior year.
• Short term Debt for Q1 2026 stood at $1.1 million, down from $1.3 million in the prior quarter.
• The five-year high for Short term Debt was $2.5 million in Q4 2024, with the low at $942000.0 in Q3 2025.
• Average Short term Debt over 3 years is $1.5 million, with a median of $1.2 million recorded in 2025.
• Peak annual rise in Short term Debt reached 46.37% in 2025, while the deepest fall reached 46.37% in 2025.
• Tracing LBRX's Short term Debt over 3 years: stood at $2.5 million in 2024, then tumbled by 46.37% to $1.3 million in 2025, then fell by 14.89% to $1.1 million in 2026.
• The last three Short term Debt figures came in at $1.1 million (Q1 2026), $1.3 million (Q4 2025), and $942000.0 (Q3 2025), per Business Quant data.

Peer Comparison